Objective: To compare the incidence of allelic imbalance (AI) in men with rapid disease progression with those who remained disease free after radical prostatectomy, with the aim of identifying genetic markers to predict prognosis and guide further treatment. Patients and methods: Tumour and normal DNA were extracted from two matched groups of 31 men with extracapsular node-negative (pT3N0) prostate cancer who had undergone radical prostatectomy. One group comprised men who developed biochemical recurrence within 2 years of surgery and one group were prostate-specific antigen (PSA) free for at least 3 years. Men were matched for Gleason grade, preoperative PSA and pathological stage. Analysis was performed by genotyping. Results: Allelic imbalance was analysed using 30 markers, and was seen in at least one marker in 57 (92%) of the cases. Deletion at marker D10S211 (10p12.1) was significantly more common in the relapse group than the non-relapse group (35 vs 5%, P ¼ 0.03). Conclusions: This study demonstrates significant association between AI on chromosome 10 and biochemical progression after radical prostatectomy.
Introduction
Since the introduction of prostate-specific antigen (PSA) testing, more men are diagnosed with organ-confined prostate cancer. 1, 2 Despite this 'stage migration', 16-48% of men will develop PSA recurrence within 5 years of radical prostatectomy (RP), [3] [4] [5] [6] [7] often as a result of micrometastatic disease present, but undetected, at the time of surgery. 8 Radical curative options are associated with side effects, including incontinence and erectile dysfunction in some patients. Current clinico-pathological markers and imaging modalities lack sufficient sensitivity at detecting micrometastatic disease. Using genetic biomarkers, patients with incurable disease may be identified before undergoing radical treatment, avoiding the inherent risks. In men who have undergone radical surgery where genetic biomarkers are subsequently identified, adjuvant therapy may be offered to improve disease outcome.
Cancer initiation and progression is a multistep process involving an accumulation of genetic changes. 9 Loss of heterozygosity frequently occurs at the site of tumour suppressor genes (TSG), and such losses can be detected by the analysis of allelic imbalance (AI). The influence of AI on the clinical outcome of prostate cancer is as yet unknown.
Allelic imbalance is the most frequently found genetic alteration in prostate cancer 10 and is reported consistently on chromosomes 1q, 3p, 5q, 6q, 7q, 8p, 9p, 10p, 10q, 11p, 11q, 12p, 13q, 16q, 17p, 17q, 18q and 21q. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The sites most frequently lost in somatic cancers include 8p, 10q, 13q, 16q and 18q, [11] [12] [13] 15, 20, 22, 23 and losses on 1q are associated with hereditary prostate cancer.
value in selecting the optimum treatment for a particular patient. The aim of this study was to compare the association of AI using 30 microsatellite markers in men with biochemical recurrence with those who remain relapse free after RP.
Patients and methods
Consent for this project was obtained from the Joint UCL/UCLH Committees on the Ethics of Human Research. The University College London radical prostatectomy database contains the clinico-pathological details of 1001 men who have undergone RP between 1988 and 2001. 2 A cohort of patients with pT3N0 prostate cancer was selected as a significant proportion (24-82%) develop biochemical recurrence after RP. 4, 7, 28, 29 Men with pT3 disease in whom lymphadenectomy was not performed, as the chance of lymph node metastases was o5%, 30 were included. Patients were categorised as having a poor outcome (relapse group) if they developed biochemical recurrence within 2 years of surgery, defined as a serum PSA level of greater than 0.2 31, 32 or 0.5 ng/ ml 33 if a less sensitive assay had been used. Men with a good outcome (non-relapse group), whose serum PSA level remained undetectable for at least 3 years after RP, were extracted for comparison. Prostate-specific antigen relapse within 2 years was the cutoff, as over 90% of men who develop biochemical recurrence within 2 years of surgery have metastatic disease. 4 In contrast, three quarters of men who subsequently relapse after 3 years develop local recurrence only. 4 Patients were excluded if they were receiving a 5 a-reductase inhibitor, or hormonal therapy pre-or postoperatively. Patients who received adjuvant radiotherapy were excluded from the non-relapse group.
Each man in the relapse group was paired with one man in the non-relapse group, matching for Gleason sum score (5, 6, 7 or 8), preoperative PSA (4-10 or 10.1-20 ng/ ml) and pathological stage (pT3a or pT3b) ( Table 1 ). The study was designed using statistical calculations based on the McNemar test for paired samples and a power of 80% to show a difference in the proportion of AI between 34 and the index tumour is the most powerful determinant of PSA failure. 35 The whole-mount section containing the index tumour was marked in areas that contained at least 70% malignant cells by the histopathologist. 12, 36 Normal tissue was obtained from the paraffin blocks of lymph nodes, or in three cases where lymphadenectomy had not been performed, tissue was obtained from the tumour-free seminal vesicles (patients 6, 27, 37). Sections (10 mm) were cut and stained with haematoxylin and eosin to aid tumour identification. Areas of cancer of greater than 0.5 cm 2 were scraped off with a scalpel, 10 and smaller areas, in patients 12 and 28, were obtained by laser capture microdissection (Arcturus). DNA extraction was performed using the Qiagen DNeasys kit (Qiagen Ltd, Qiagen House, Fleming Way, Crawley, West Sussex, UK). Thirty microsatellite markers covering 27 regions on 17 chromosomal arms (1q, 2q, 5q, 6q, 7q, 8p, 10p, 10q, 11p, 11q, 12p, 13q, 15q, 16q, 18q, 19q and 21q) were used ( Table 2) . Polymerase chain reaction (PCR) was performed using 0.5 ml of DNA, 2.5 mM MgCl 2 , 8 pM sense and antisense microsatellite marker, 2 mM dNTP, 1.5 ml 10 Â reaction buffer (750 mM Tris-HCl, pH 8.8) and 0.15 ml (E0.75 U) Red Hots Taq polymerase (ABgene, ABgene House, Epson, Surrey, UK) in 6.65 ml di-iodinised water, made up to a final volume of 15 ml. Amplification conditions were 15 min at 951C, 36 cycles of denaturation at 951C for 45 s, annealing at 53-581C for 45 s and extension at 721C for 45 s. The final extension step was at 721C for 10 min. Each PCR and AI analysis was performed independently at least twice; consequently, the results were derived from over 7400 PCR reactions. Two controls were used, the first where DNA was replaced by water and the second where DNA was replaced by reaction mix. A sample of 2-4 ml of PCR product was run on the ABI A3700 (Applied Biosystems, Foster City, CA, USA) DNA sequencer.
Two researchers (SRJB and MW) examined each electropherogram independently. A relative allele ratio of less than 0.7, which correlates with an allele loss of approximately 40%, was defined as AI (Figure 1 ), as has been previously validated. 14 
Results
In the 31 matched pairs, the median preoperative PSA was 10.2 ng/ml (range 5.1-18.6) in the relapse group and 10.0 ng/ml (range 5.1-17.8) in the non-relapse group (Wilcoxon's signed rank test, P ¼ 0.39). The median PSA free follow-up for the non-relapse group was 53 months (range 36-87). The median time to PSA recurrence in the relapse group was 9 months (range 3-21). The mean age at the time of surgery was 59.6 years (s.d. 6.1) in the relapse group and 64 years (s.d. 6.2) in the non-relapse group (paired t-test, Po0.01).
At least one positive surgical margin was present in 21 patients in the relapse group and 20 patients in the nonrelapse group. Neither the site (apical or circumferential, intra or extraprostatic) nor the number of positive surgical margins (negative, solitary or multiple) was significantly different between the two groups (Wilcoxon's signed rank test, P ¼ 0.11 and P ¼ 1.0, respectively).
Thirty microsatellite markers were used to assess differences between 62 men with pT3N0 disease (see Tables 3 and 4) . Allelic imbalance at one or more loci was seen in 57 (92%) of the 62 patients. Five patients who did not show AI, three men in the relapse group (24, 25, 64) and two in the non-relapse group (30, 61) ( Table 3) .
The study was designed to compare the matched pairs of cancers, but this analysis was not possible for three reasons. Some of the electropherograms could not be interpreted; despite repeated analysis, some were uninformative because the loci were homozygous; and some showed microsatellite instability. As the numbers of matched pairs were inadequate for statistical analysis using the McNemar test, the proportions of AI in the two groups were compared using Fisher's exact test. One marker, D10S211 at 10p12, demonstrated significantly greater AI in the poor-prognosis group than in the goodprognosis group (35 vs 5%, respectively, Fisher's exact test, P ¼ 0.03).
Several loci demonstrated a marked increase in AI in the relapse compared with the non-relapse groups. These included D2S222 (29 vs 8%), D6S314 (25 vs 11%), D8S136 (50 vs 29%), NEFL (71 vs 55%), D12S1697 (31 vs 17%), D13S269 (19 vs 4%), D15S1232 (38 vs 18%) and D18S541 (25 vs 0%) in the relapse and non-relapse groups, respectively. In contrast, some loci showed a higher incidence of AI in the non-relapse group. These were D1S158 (14 vs 35%), D1S422 (17 vs 27%), D5S500 (13 vs 23%), D11S2000 (19 vs 31%), D12S89 (14 vs 29%) and D16S413 (13 vs 24%) in the relapse and non-relapse groups, respectively.
Discussion
Many sites of AI have been identified in prostate cancer; their prognostic significance is currently not known. The aim of this study was to determine the association between AI at 27 loci and biochemical relapse after RP.
To examine differences in AI, patients were matched for the factors proven to be of prognostic importance. 37 By matching for and thereby excluding the influence of the known prognostic factors, this study had the potential to directly assess the prognostic significance of AI at each locus.
Allelic imbalance on chromosome 10 is a common event in several solid tumours, including renal cell cancer, 38 examined AI on chromosome 10 in 35 radical prostatectomy specimens using 12 markers. Overall, six (17%) tumours demonstrated loss of 10p loci only, five (14%) showed losses of 10q loci only and 14 (40%) had losses of both 10p and 10q loci. Six (18%) showed loss at D10S211 (10p12.1), which is similar to our series, where seven (19%) of 36 informative cases demonstrated AI at this locus. In another study, AI was examined in 64 clinically localised and 19 locally advanced or metastatic prostate cancers. 44 Nine (20% of informative loci) of 64 localised cases showed AI at one or more of 12 microsatellite regions. Of these nine selected cases, two (33%) of six informative loci had AI at D10S211 and one (17%) of six had AI at D10S587 3) . In a study of 48 Japanese men, losses on chromosome 10 were significantly more frequent in advanced and hormone refractory prostate cancer compared to localised cases. 45 Although losses at 10p12.1 are a frequent finding in advanced prostate cancer, their role in predicting biochemical outcome in RP patients needs to be verified in an independent cohort.
Loss of 10q22-24, the site of at least two putative tumour suppressor genes, PTEN and MXI1, is the most commonly reported site of deletion on chromosome 10 in prostate cancer, with rates of 20-50% of informative cases described. [46] [47] [48] [49] Two other sites on chromosome 10, 10p and 10q26, are also deleted in association with or independent of 10q22-24 losses. 39, [43] [44] [45] In our study, two loci on 10q, 10q25.1 and 10q25, were examined, but neither showed a significant difference between the relapse and non-relapse groups.
Several loci demonstrated marked, although not statistically significant, differences between the relapse and non-relapse groups, including the region 2q23.1 (D2S222); six (29%) of 21 relapse patients and two (8%) of 25 non-relapse patients region showed AI (P ¼ 0.07). This region has not been extensively studied in prostate cancer. Saric et al. 22 reported one (6%) of 17 men undergoing RP for clinically localised disease and four (23%) of 23 metastasis samples had AI at this locus. The current study suggests an association with poor outcome after surgery although further studies are required to confirm these findings.
In our study, three (25%) of 12 informative relapse patients and one (11%) of nine informative non-relapse patients demonstrated AI at 6q16.3-27 (marker D6S314). Cooney et al. 17 demonstrated that this region is commonly deleted in RP specimens. Although no association with 6q losses and biochemical relapse was found, only 10 patients relapsed over a short follow-up of 8 months. 17 Allelic imbalance occurred in five (19%) of 26 relapse patients and one (4%) of 25 non-relapse patients in the region 13q21 (marker D13S269). Deletions of 13q are frequently reported in prostate cancer and these are associated with poorly differentiated or metastatic disease. 50 The chromosomal region 12p12-13 contains the TSG p27/kip1, and deletion of this region is associated with metastasis in prostate cancer. 27 Allelic imbalance was reported in 23% of 60 primary prostate tumours compared with 47% of 19 metastatic lesions. 27 Of 11 patients with multiple metastases, seven demonstrated AI in this region, and the pattern was identical in all the metastases examined from each individual patient as well as in the primary tumour. These data suggest that loss of this region occurs in primary tumours before distant spread and may be a critical step in prostate cancer metastasis. In the current study, 31% of the relapse patients compared with 17% of the non-relapse men had AI at 12p12.3 (P ¼ 0.28).
Losses on 8p play a key role in initiation and progression of prostate cancer, and the three markers on the short arm of chromosome 8 had some of the highest rates of AI of the 30 markers studied. At least two distinct regions of loss have been reported. 51, 52 Loss of 8p12-21 is an early event in prostate carcinogenesis, occurring in HGPIN and early invasive disease, whereas loss of 8p22 is a late event, found more commonly in advanced cancers. 53 Marker D8S136 on 8p12-22 demonstrated AI in 39% of informative patients, marker NEFL at 8p21.3 in 62% and marker D8S1991 at 8p22 in 47%. All three markers demonstrated a higher rate of AI in the relapse patients than the non-relapse individuals. However, this study, in common with previous studies, 12, 54 failed to show a statistical correlation between losses of 8p and biochemical progression after RP.
Locus 18q 21.1 is also associated with metastatic potential in prostate cancer. 22, 55 The overall incidence of AI at this locus was low; two (10%) of 19 informative cases; however, both patients with AI at this locus developed biochemical relapse, one at 13 months (patient 2) and one at 3 months (patient 43). Both these patients had good pathological features after surgery -Gleason 7 disease, specimen confined and surgical margin negative disease -and yet developed early biochemical recurrence. Using conventional criteria, these men would be expected to have a PSA free survival of 68-80% at 7 years. 56 This highlights the need for better prognostic markers, although the incidence of AI at 18q21.1 alone is too low to be useful in the majority of men.
The TSG KAI1 gene is located at 11p11, close to marker D11S902. Deletion of this region is associated with metastatic prostate cancer 21, 22 and the KAI1 gene has been shown in metastatic rat models to reduce metastatic potential. 57 Only one (3%) of 36 informative cases had AI at this locus, although the patient (79) who had AI at this locus relapsed within 12 months of surgery. The low rate of AI at this locus and at 18q21.1 may represent background deletion, reported to be 2-10% in tumour tissues 22, 58 rather than deletion of a significant TSG. Despite using 30 markers at areas identified as commonly deleted in prostate cancer, only one marker was significantly different between the groups. This may be because although many genetic changes occur during the development of recurrent prostate cancer, only a small proportion of the total are essential for disease progression. Furthermore, AI does not detect small deletions, point mutations or gene amplification, which may be important in progression. Identifying which of Under each allelic peak, the first box confirms the correct size of product, the second the amplitude and the third the area under the peak. The ratio of the amplitudes of the cancer peaks is divided by the ratio of the amplitude of the control peaks. Allelic imbalance is defined as o0.7.
AI and biochemical outcome after RP SRJ Bott et al A limitation of the study was that despite a database of over 1000 men, only 62 men could be matched. This difficulty is likely to increase with time as more men are presenting earlier in the disease process and therefore fewer are developing biochemical recurrence. Technical problems included the number of patients in whom a result could not be obtained despite repeating the DNA extraction and PCR processes. Archival DNA is fragmented and the formalin fixation process in large RP specimens is relatively slow, resulting in poor-quality DNA for amplification. Perhaps by optimising the PCR conditions for each set of primers and each DNA sample, it would have been possible to increase the success rate, but given the large scale of the study and the limited amount of DNA, this approach was not feasible.
This study examined the DNA from the RP specimen. To benefit patients before they undergo radical treatment, genetic markers must be identified in the diagnostic prostate biopsy samples; future studies could examine whether the changes identified are also present in this tissue.
Conclusion
Allelic imbalance has been used to predict prognosis and treatment response in a number of malignancies. Our study suggests a significant association between loss of a locus at chromosome 10p12.1 and biochemical progression after RP. The small number of patients with AI at 11p11 and 18q21.1 developed biochemical relapse, despite in some cases favourable pathological prognostic features. Confirming that the AI findings identified in the RP specimen are also present in the diagnostic biopsy may, in the future, enable treatment to be tailored to the individual patient. AI and biochemical outcome after RP SRJ Bott et al
